Novel immunotherapies in multiple myeloma - chances and challenges

被引：24
作者：
Rasche, Leo [1 ,2 ]
Wasch, Ralph [3 ]
Munder, Markus [4 ,5 ]
Goldschmidt, Hartmut [6 ,7 ]
Raab, Marc S. [6 ,8 ]
机构：
[1] Univ Hosp Wurzburg, Dept Internal Med 2, Wurzburg, Germany
[2] Univ Hosp Wurzburg, Mildred Scheel Early Career Ctr, Wurzburg, Germany
[3] Univ Freiburg, Fac Med, Univ Med Ctr, Dept Internal Med 1, Freiburg, Germany
[4] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Med 3, Mainz, Germany
[5] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Res Ctr Immunotherapy, Mainz, Germany
[6] Univ Hosp Heidelberg, Dept Internal Med 5, Heidelberg, Germany
[7] Natl Ctr Tumor Dis NCT, Heidelberg, Germany
[8] German Canc Res Ctr, CCU Mol Hematol Oncol, Heidelberg, Germany
来源：
HAEMATOLOGICA | 2021年 / 106卷 / 10期
关键词：
T-CELL THERAPY; CAR-T; EXPRESSION; CD38;
D O I：
10.3324/haematol.2020.266858
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In this review article, we summarize the latest data on antibody-drug conjugates, bispecific T-cell-engaging antibodies, and chimeric antigen receptor T cells in the treatment of multiple myeloma. We discuss the pivotal questions to be addressed as these new immunotherapies become standard agents in the management of multiple myeloma. We also focus on the selection of patients for these therapies and speculate as to how best to individualize treatment approaches. We see these novel immunotherapies as representing a paradigm shift. However, despite the promising preliminary data, many open issues remain to be evaluated in future trials.
引用
收藏
页码：2555 / 2565
页数：11
相关论文
共 61 条
  • [1] T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
    Ali, Syed Abbas
    Shi, Victoria
    Maric, Irina
    Wang, Michael
    Stroncek, David F.
    Rose, Jeremy J.
    Brudno, Jennifer N.
    Stetler-Stevenson, Maryalice
    Feldman, Steven A.
    Hansen, Brenna G.
    Fellowes, Vicki S.
    Hakim, Frances T.
    Gress, Ronald E.
    Kochenderfer, James N.
    [J]. BLOOD, 2016, 128 (13) : 1688 - 1700
  • [2] Berdeja JG, 2020, J CLIN ONCOL, V38
  • [3] T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
    Brudno, Jennifer N.
    Maric, Irina
    Hartman, Steven D.
    Rose, Jeremy J.
    Wang, Michael
    Lam, Norris
    Stetler-Stevenson, Maryalice
    Salem, Dalia
    Yuan, Constance
    Pavletic, Steven
    Kanakry, Jennifer A.
    Ali, Syed Abbas
    Mikkilineni, Lekha
    Feldman, Steven A.
    Stroncek, David F.
    Hansen, Brenna G.
    Lawrence, Judith
    Patel, Rashmika
    Hakim, Frances
    Gress, Ronald E.
    Kochenderfer, James N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (22) : 2267 - +
  • [4] TAK-169, a Novel Recombinant Immunotoxin Specific for CD38, Induces Powerful Preclinical Activity Against Patient-Derived Multiple Myeloma Cells
    Bruins, Wassilis S. C.
    Zheng, Wenrou
    Higgins, Jack P.
    Willert, Erin K.
    Newcomb, John
    Dash, Ajeeta B.
    Van de Donk, Niels W. C. J.
    Zweegman, Sonja
    Mutis, Tuna
    [J]. BLOOD, 2020, 136
  • [5] Targeted Therapy With Immunoconjugates for Multiple Myeloma
    Bruins, Wassilis S. C.
    Zweegman, Sonja
    Mutis, Tuna
    van de Donk, Niels W. C. J.
    [J]. FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [6] TNB383B.0001: A Multicenter, Phase 1, Open-Label, Dose-Escalation Andexpansion Study of TNB-383B, a Bispecific Antibodytargeting BCMA in Subjects with Relapsed or Refractorymultiple Myeloma
    Buelow, Ben
    D'Souza, Anita
    Rodriguez, Cesar
    Vij, Ravi
    Nath, Rajneesh
    Snyder, Melinda
    Pham, Duy
    Patel, Ashwin
    Iyer, Suhasini
    [J]. BLOOD, 2019, 134
  • [7] A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
    Chari, Ajai
    Berdeja, Jesus G.
    Oriol, Albert
    van de Donk, Niels W. C. J.
    Rodriguez, Paula
    Askari, Elham
    Mateos, Maria-Victoria
    Minnema, Monique C.
    Verona, Raluca
    Girgis, Suzette
    Prior, Thomas
    Hilder, Brandi W.
    Russell, Jeffery
    Goldberg, Jenna D.
    Krishnan, Amrita
    [J]. BLOOD, 2020, 136
  • [8] Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma
    Cohen, Adam D.
    Harrison, Simon J.
    Krishnan, Amrita
    Fonseca, Rafael
    Forsberg, Peter A.
    Spencer, Andrew
    Berdeja, Jesus G.
    Laubach, Jacob P.
    Li, Mengsong
    Choeurng, Voleak
    Vaze, Anjali
    Samineni, Divya
    Sumiyoshi, Teiko
    Cooper, James
    Fine, Bernard M.
    Trudel, Suzanne
    [J]. BLOOD, 2020, 136
  • [9] B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma
    Cohen, Adam D.
    Garfall, Alfred L.
    Stadtmauer, Edward A.
    Melenhorst, J. Joseph
    Lacey, Simon F.
    Lancaster, Eric
    Vogl, Dan T.
    Weiss, Brendan M.
    Dengel, Karen
    Nelson, Annemarie
    Plesa, Gabriela
    Chen, Fang
    Davis, Megan M.
    Hwang, Wei-Ting
    Young, Regina M.
    Brogdon, Jennifer L.
    Isaacs, Randi
    Pruteanu-Malinici, Iulian
    Siegel, Don L.
    Levine, Bruce L.
    June, Carl H.
    Milone, Michael C.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2019, 129 (06) : 2210 - 2221
  • [10] First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial
    Costa, Luciano J.
    Wong, Sandy W.
    Bermudez, Arancha
    de la Rubia, Javier
    Mateos, Maria-Victoria
    Ocio, Enrique M.
    Rodriguez-Otero, Paula
    San-Miguel, Jesus
    Li, Shaoyi
    Sarmiento, Rafael
    Lardelli, Pilar
    Gaudy, Allison
    Boss, Isaac
    Kelly, Lisa M.
    Burgess, Michael R.
    Hege, Kristen
    Bensinger, William I.
    [J]. BLOOD, 2019, 134
1234567